KEY BENEFITS AND USES
QUESTIONS ANSWERED
• Where is my product positioned vs. competitors in the treatment journey?
• What are physicians’ most frequent treatment sequences—who is
benefiting and how can I defend my assets share and position?
• What are the market-relevant treatment scenarios according to oncology
experts?
• Where are the untapped business opportunities that I can capitalize
upon?
• How can I optimize trial design and ensure a competitive edge for my
pipeline asset?
GEOGRAPHIES
United States
PRIMARY MARKET RESEARCH
Survey of ~100 U.S. physicians
2019 COVERAGE
Colorectal Cancer (US)
Multiple Myeloma (US)
Non-Hodgkin’s Lymphoma and Chronic Lymphocytic Leukemia (US)
Non-Small-Cell Lung Cancer (US)
Ovarian Cancer (US)
Prostate Cancer (US)
Renal Cell Carcinoma (US)
KEY FEATURES
PRODUCT DESCRIPTION
Treatment Sequencing provides disease-specific, sequential treatment
patterns in market-relevant treatment scenarios and drug share mapped to
treatment journey. The quantitative sequencing analysis illuminates drug
positioning through primary market research-based insights from physicians
and DRG oncology experts’ assumptions.